Skip to content

Saxenda vs Zepbound: approved uses, forms, cost and coverage

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Saxenda vs Zepbound compares a once-daily injection with a once-weekly one. Saxenda (liraglutide, Novo Nordisk) and Zepbound (tirzepatide, Eli Lilly) are both approved for long-term weight reduction, and Zepbound also for obstructive sleep apnea. Zepbound self-pay through LillyDirect runs from $299 to $449 a month. Saxenda's list price is $1,349.02.

Source: LillyDirect self-pay

Key takeaways

  • Novo Nordisk has announced Saxenda will be discontinued, with last shipments to wholesalers in late January 2027.
  • Only Zepbound is approved for moderate to severe obstructive sleep apnea, in adults with obesity.
  • Only Saxenda's label includes younger patients: age 12 and older with obesity and body weight above 60 kg.
  • Paying cash? LillyDirect sells Zepbound vials or KwikPen from $299 to $449 a month, with on-time refills from 7.5 mg.
  • No label equates a Saxenda dose with a Zepbound dose. Your prescriber decides where you start.

Saxenda vs Zepbound, side by side

From each FDA label and our verified price records
SaxendaZepbound
Active ingredientliraglutidetirzepatide
MakerNovo NordiskEli Lilly and Company
FDA-approved uses
  • Reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity
  • Reduce excess body weight and maintain weight reduction long term in adults with overweight in the presence of at least one weight-related comorbid condition
  • reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related comorbid condition
  • moderate to severe obstructive sleep apnea (OSA) in adults with obesity
How it is takendaily (multi-dose pen)weekly (multi-dose pen); weekly (multi-dose vial); weekly (single-dose pen); weekly (single-dose vial)
Strengths0.6 to 3 mg2.5 to 15 mg
Label starting dose
  • 0.6 mg daily
  • 2.5 mg weekly
Cheapest verified self-payNo self-pay price listed$449 per fill at 15 mg
LillyDirect self-pay
With covering commercial insuranceNo savings-card price listed$25 with the manufacturer card
Medicare GLP-1 BridgeNoYes: KwikPen (multi-dose, 4 weekly doses)
LabelRevised: 6/2026 (DailyMed version 22)Revised: 8/2026 (DailyMed version 40)
Saxenda: most common reactions on the label · Adults with overweight or obesity in 5 double-blind, placebo-controlled trials, treated for up to 56 weeks (3 trials), 52 weeks (1 trial) and 32 weeks (1 trial). The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 2: Saxenda N=423, placebo N=212), defined as blood glucose below 54 mg/dL with or without symptoms.
ReactionSaxendaPlacebo
Nausea39.3%13.8%
Diarrhea20.9%9.9%
Constipation19.4%8.5%
Vomiting15.7%3.9%
Injection Site Reaction13.9%10.5%
Headache13.6%12.6%
Zepbound: most common reactions on the label · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
Reaction15 mgPlacebo
Nausea28%8%
Diarrhea23%8%
Vomiting13%2%
Constipation11%5%
Abdominal Pain10%5%
Dyspepsia10%4%

Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.

Saxenda and Zepbound are both injections approved for weight management, and that’s where most of the resemblance ends. They contain different drugs from different makers, one taken every day and one every week. And Novo Nordisk has announced that Saxenda will be discontinued, which is why many people taking Saxenda are reading about Zepbound. This page compares the two using the FDA labels (Revised: 6/2026 (DailyMed version 22) for Saxenda, Revised: 8/2026 (DailyMed version 40) for Zepbound) and our price records.

Saxenda or Zepbound: which suits whom?

  • You’re an adult who wants a weekly injection and a published cash price. Zepbound has self-pay prices from $299 a month, a savings card, and a route through the Medicare GLP-1 Bridge.
  • You have moderate to severe obstructive sleep apnea and obesity. Zepbound is the only one of the two approved for that, in adults.
  • The patient is a teenager. Saxenda is the only one of the two with a use in younger patients, from age 12 with obesity and body weight above 60 kg. Zepbound hasn’t been established as safe and effective in children.
  • You’re an adult already doing well on Saxenda. It remains an option while supply continues. Novo Nordisk has announced last shipments to wholesalers in late January 2027.
  • Your plan covers one and not the other. That will usually settle it. Insurers treat them as unrelated products.

Each label reports its own studies, and we don’t line their weight results up against each other. If you’re on Saxenda now, ask your prescriber what comes next and when, and ask your plan which weight-management medicines it covers.

What is each approved for?

Both are approved to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition. The Zepbound label says it’s to be used with a reduced-calorie diet and increased physical activity.

The differences:

  • Sleep apnea. Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity. Saxenda isn’t.
  • Age. Saxenda’s label includes patients aged 12 and older with obesity and body weight above 60 kg. Zepbound’s is for adults.
  • What not to combine. Saxenda isn’t recommended with other liraglutide products or any other GLP-1 receptor agonist. Zepbound isn’t recommended with other tirzepatide products or any GLP-1 receptor agonist. The two aren’t used together.

How do the forms differ?

Saxenda comes one way: a multi-dose pen containing 18 mg of liraglutide, dialed to the dose you’re on. It delivers 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg. Pen needles aren’t included. Pens are sold in cartons of 3 or 5.

Zepbound comes several ways, all in the same six strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg):

  • a single-dose pen, four to a carton, which is the form the covered-insurance savings card applies to;
  • a single-dose vial, drawn up with a syringe and needle you get separately;
  • a KwikPen holding four weekly doses, used with pen needles. The label says it isn’t recommended for self-administration by people who are visually impaired.

The form matters for Zepbound’s price and coverage in a way it doesn’t for Saxenda. The LillyDirect self-pay prices are for the vial and the KwikPen, and the Medicare GLP-1 Bridge covers the KwikPen only. The pen vs vial vs pill comparer shows the forms side by side.

How do the doses compare?

Saxenda, daily. The label raises the dose once a week: 0.6 mg in week 1, then 1.2 mg, 1.8 mg, 2.4 mg and 3 mg from week 5. For adults, 3 mg daily is the recommended dosage, and lower doses are only for stepping up.

Zepbound, weekly. The label starts at 2.5 mg once weekly for 4 weeks, a dose that isn’t approved for maintenance (the dose you stay on). It then moves to 5 mg, with further increases of 2.5 mg after at least 4 weeks on the current dose. The recommended maintenance dose for weight reduction is 5 mg, 10 mg or 15 mg, and the maximum is 15 mg.

Saxenda has one adult target dose. Zepbound has three maintenance doses. Liraglutide milligrams per day and tirzepatide milligrams per week are separate scales, and no label converts between them.

Saxenda’s label also carries a review point that Zepbound’s doesn’t. Adults who haven’t lost at least 4% of their baseline body weight 16 weeks after starting Saxenda should stop it.

The titration schedule tool turns either schedule into dates, and the missed dose tool applies each label’s own rule.

What does each cost?

Zepbound:

  • LillyDirect self-pay, vial or KwikPen: $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg, 10 mg, 12.5 mg and 15 mg.
  • The price for 7.5 mg and above holds only if you buy each refill within 45 days of getting the last one. Refill later and the regular price applies: $499 for 7.5 mg and $699 for the higher doses. Our page on the 45-day refill rule explains the timing.
  • Savings card with commercial insurance that covers Zepbound: as little as $25 per fill of the single-dose pen.
  • List price (the full price before any discount): $1,086.37 per fill for the single-dose pen.

Saxenda: one price, the list price of $1,349.02. Novo Nordisk states it without naming the supply period, so we don’t turn it into a monthly figure. The Saxenda savings offer closed to new enrollees on June 30, 2023.

If you pay cash, remember the Zepbound vial needs syringes and the KwikPen needs pen needles, bought separately. The Zepbound cost guide, the Saxenda cost page and the cost calculator have the detail.

Does insurance or Medicare cover them?

Commercial coverage for weight-management medicines differs from plan to plan, and some employers exclude the category. Ask about each by name, and ask whether prior authorization (the plan’s approval before it pays) applies. The Zepbound savings card works only with commercial insurance and excludes anyone on a government program.

Medicare draws a clear line between them. The Part D statute excludes drugs when used for weight loss.

  • Saxenda has no approved use outside weight reduction, and it isn’t one of the products in the Medicare GLP-1 Bridge.
  • Zepbound has two routes. The Bridge covers the Zepbound KwikPen for eligible people with Part D at a $50 copay per one-month supply, through December 31, 2027. And CMS names Zepbound for moderate to severe obstructive sleep apnea in adults with obesity as a use that can be covered under the basic Part D benefit.

The Bridge eligibility checker walks through the criteria, and does Medicare cover Zepbound covers both routes.

How do the side effects compare?

Stomach and bowel effects are the most common on both labels. The figures below are from each medicine’s own trials and describe that medicine only.

Saxenda. In the label’s adult trials, nausea was reported by 39.3 percent of patients on Saxenda versus 13.8 percent on placebo, and diarrhea by 20.9 percent versus 9.9 percent. Approximately 68% of patients on Saxenda and 39% on placebo reported gastrointestinal disorders.

Zepbound. In the label’s pooled weight trials (Study 1 and Study 2), nausea was reported by 25, 29 and 28 percent of people on 5 mg, 10 mg and 15 mg, versus 8 percent on placebo. Diarrhea was reported by 19, 21 and 23 percent, versus 8 percent. Gastrointestinal reactions overall were reported by 56 percent at each dose, compared with 30 percent on placebo. The label says most nausea, vomiting and diarrhea occurred during dose escalation, while the dose was going up, and decreased over time.

Both carry a boxed warning about thyroid C-cell tumors. Neither should be used by people with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or with MEN 2 (an inherited condition linked to it). Both labels say to discontinue the medicine when a pregnancy is recognized.

Can you switch from Saxenda to Zepbound?

A prescriber can make that change, but the labels don’t say how. The Zepbound label gives no instructions for switching from another GLP-1 medicine and states only its 2.5 mg starting dose. No label equates a Saxenda dose with a Zepbound dose, and we don’t convert doses between drugs.

A different drug from a different maker usually means a new prior authorization and a new device to learn, so book the appointment before your Saxenda supply becomes uncertain.

The switching guides and the switching planner show what each label says. If semaglutide is also on the table, read Saxenda vs Wegovy, or browse every pairing on the comparison hub.

Frequently asked questions

How is Zepbound different from Saxenda?

They're different drugs from different companies. Zepbound is tirzepatide from Eli Lilly, injected once a week, approved for weight reduction in adults and for moderate to severe obstructive sleep apnea in adults with obesity. Saxenda is liraglutide from Novo Nordisk, injected once a day, approved for weight reduction in adults and in patients aged 12 and older with obesity.

How much do Saxenda and Zepbound cost without insurance?

Zepbound vials and the KwikPen cost $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg to 15 mg through LillyDirect with on-time refills. Novo Nordisk's list price for Saxenda is $1,349.02.

Can I go from Saxenda to Zepbound?

That's your prescriber's decision, and the labels don't provide a conversion. The Zepbound label gives no instructions for switching from another medicine. It states only its starting dose, 2.5 mg once weekly. It also says Zepbound shouldn't be combined with any GLP-1 receptor agonist, which includes Saxenda.

Can teenagers take Saxenda or Zepbound?

Saxenda's label includes patients aged 12 years and older with obesity and a body weight greater than 60 kg. Zepbound's label says its safety and effectiveness have not been established in children. For anyone under 18, that difference is likely to decide the question, together with the prescriber's judgment.

Which is covered by Medicare, Saxenda or Zepbound?

Part D excludes drugs when used for weight loss, and Saxenda has no other approved use. Zepbound has two routes. The Medicare GLP-1 Bridge covers the Zepbound KwikPen for eligible Part D patients at a $50 monthly copay, and CMS names Zepbound for moderate to severe obstructive sleep apnea as a use Part D can cover.

Sources (23)

  1. 1.
    FDA label (DailyMed): Saxenda prescribing information, Instructions for Use
    “It contains 18 mg of liraglutide, and you can select doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3 mg.”
  2. 2.
    FDA label (DailyMed): Saxenda prescribing information, Instructions for Use
    “Your pen is made to be used with disposable needles up to a length of 8 mm. Pen needles are not included with your Saxenda pen.”
  3. 3.
    FDA label (DailyMed): Saxenda prescribing information, section 2.2
    “Evaluate the change in body weight 16 weeks after initiating SAXENDA and discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.”
  4. 4.
    FDA label (DailyMed): Saxenda prescribing information, section 1
    “SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  5. 5.
    FDA label (DailyMed): Saxenda prescribing information, section 8.1
    “Additionally, weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus, and discontinue SAXENDA”
  6. 6.
    FDA label (DailyMed): Saxenda prescribing information, section 4
    “Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
  7. 7.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Instruct patients using ZEPBOUND vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”
  8. 8.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “ZEPBOUND KwikPen is not recommended for self-administration by those who are visually impaired.”
  9. 9.
    FDA label (DailyMed): Zepbound prescribing information, section 2.2
    “The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
  10. 10.
    FDA label (DailyMed): Zepbound prescribing information, section 2.1
    “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
  11. 11.
    FDA label (DailyMed): Zepbound prescribing information, section 1
    “ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  12. 12.
    FDA label (DailyMed): Zepbound prescribing information, section 8.4
    “The safety and effectiveness of ZEPBOUND have not been established in pediatric patients.”
  13. 13.
    FDA label (DailyMed): Zepbound prescribing information, section 8.1
    “Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized (see Clinical Considerations).”
  14. 14.
    FDA label (DailyMed): Zepbound prescribing information, section 4
    “ZEPBOUND is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].”
  15. 15.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  16. 16.
    CMS: Information for Part D Plans
    “Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.